Interestingly, it was shown that CD62L+ or CCR7+ Tregs are more potent to suppress GVHD than CD62- or CCR7- counterparts presumably due to facilitating Treg to entering into the lymph nodes as priming sites of GVHD (8–10). The gene discussed is SELL; the disease is graft versus host disease.